Literature DB >> 9065593

Midkine expression in human breast cancers: expression of truncated form.

I Miyashiro1, T Kaname, E Shin, E Wakasugi, T Monden, Y Takatsuka, N Kikkawa, T Muramatsu, M Monden, T Akiyama.   

Abstract

The expression of midkine (MK), a growth/differentiation factor, was assessed in 34 surgically resected specimens of primary breast cancer or mastopathy. Using reverse transcriptase-polymerase chain reaction (RT-PCR) analysis, all of the non-cancerous and cancerous tissues were found to express MK except for one breast cancer specimen. Northern blot analysis revealed that MK mRNA was also expressed in the normal breast tissues examined. Immunohistochemical analysis of the MK protein was performed on a limited number of the specimens, showing that some cancerous tissues were immunoreactive with anti-MK antibodies. Furthermore, using RT-PCR analysis, expression of not only the wild-type but also a truncated form of MK, which was recently found in various human tumor cell lines, was detected in 6 of 26 cancerous tissues but not in non-cancerous tissues.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9065593     DOI: 10.1023/a:1005748728351

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  14 in total

Review 1.  Pancreatic cancer.

Authors:  C Güngör; B T Hofmann; G Wolters-Eisfeld; M Bockhorn
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

2.  Promotion of self-renewal of embryonic stem cells by midkine.

Authors:  Xing Yao; Zhou Tan; Bin Gu; Rong-rong Wu; Yu-kan Liu; Li-cheng Dai; Ming Zhang
Journal:  Acta Pharmacol Sin       Date:  2010-05       Impact factor: 6.150

Review 3.  Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases.

Authors:  D R Jones
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

4.  Over-expressed and truncated midkines promote proliferation of BGC823 cells in vitro and tumor growth in vivo.

Authors:  Qing-Ling Wang; Hui Wang; Shu-Li Zhao; Ya-Hong Huang; Ya-Yi Hou
Journal:  World J Gastroenterol       Date:  2008-03-28       Impact factor: 5.742

5.  Midkine mRNA is overexpressed in pancreatic cancer.

Authors:  Seiji Ohhashi; Kenoki Ohuchida; Kazuhiro Mizumoto; Takuya Egami; Jun Yu; Lin Cui; Hiroki Toma; Shunichi Takahata; Toshinaga Nabae; Masao Tanaka
Journal:  Dig Dis Sci       Date:  2008-08-21       Impact factor: 3.199

6.  The advances of Midkine with peripheral invasion in pancreatic cancer.

Authors:  Jun Yao; Wen-Yao Li; She-Gan Gao
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

Review 7.  Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target.

Authors:  Panagiota S Filippou; George S Karagiannis; Anastasia Constantinidou
Journal:  Oncogene       Date:  2019-12-04       Impact factor: 9.867

Review 8.  Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases.

Authors:  Takashi Muramatsu
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2010       Impact factor: 3.493

Review 9.  Midkine: a promising molecule for drug development to treat diseases of the central nervous system.

Authors:  Takashi Muramatsu
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

10.  Midkine as a prognostic biomarker in oral squamous cell carcinoma.

Authors:  K Ota; H Fujimori; M Ueda; S Shiniriki; M Kudo; H Jono; Y Fukuyoshi; Y Yamamoto; H Sugiuchi; H Iwase; M Shinohara; Y Ando
Journal:  Br J Cancer       Date:  2008-08-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.